摘要
目的:观察中剂量阿糖胞苷联合氟达拉滨(FA方案)在急性非淋巴细胞白血病巩固化疗中的疗效。方法:治疗组采用FA方案巩固化疗,Flu 30mg/(m2.d)d1-3,Ara-c(1.0-2.0)g/q12h×3d,对照组采用常规剂量化疗方案,比较两组的不良反应,应用FCM以白血病细胞(leukemiam cell,LC)特异分化抗原为标志监测两组残留病灶(minimal residual disease,MRD),并与传统骨髓形态学结果进行比较。结果:FA方案组MRD逐渐减少,3年复发率48%,对照组3年复发率64%,且容易出现髓外复发,两组差异率有统计学意义(P<0.05)。所有FA方案组患者均发生IV级骨髓抑制现象,明显强于对照组(P<0.05),其他非血液系统不良反应包括胃肠道反应、黏膜炎、肝功能损伤;大多数不良反应能被患者耐受,FA组与对照组无显著差异。结论:FA方案可以清除缓解后残留的白血病细胞,又能预防中枢白血病,不良反应轻,体内代谢快,在急性非淋巴细胞白血病巩固化疗中具有重要的作用。
Objective：To study the theprapeutic effect of patient with acute myeloid leukemia in remission treated with intermediated-dose arabinoside and fludarabine（FA regimen）.Methods： Twenty-five cases in treatment group of consolidation chemotherapy were treated with FA regimen,fludarabine phosphate 30mg/（m2·d）,d1-3,cytarabine（Ara-C）（1.0-2.0）g/q12h×3d.Another 25 cases in control group were treated with conventional treatment regimen.Results： MRD decreased gradually and the recurrence rate for 3 years was 48% in FA group,the clinical efficacy was superior than control group（P0.05）.Major toxicity of FA regimen was myelosuppression,grade IV hematologic toxicity occurred in all patients,nonhematology complications sonsisted of gastrointestinal side effects,mucositis,liver toxicity,which were mild to moderate and could be alleviated with supportive therapy.Conclusion： FA regimen is an important regimen for acute non-lymphocytic leukemia,which may remove residual leukemiam cells in remission and prevent central nervous system leukemia.It has light sides and fast metabolism.
出处
《现代肿瘤医学》
CAS
2012年第4期794-796,共3页
Journal of Modern Oncology
基金
延安大学附属医院研究生创新科研基金(编号:10YJ16)
关键词
中剂量阿糖胞苷
氟达拉滨
急性非淋巴细胞白血病
巩固化疗
残留病灶
intermediated-dose arabinoside
fludarabine
acute non-lymphocytic leukemia
consolidation chemotherapy
minimal residual disease
